NioCorp or the
Company )
(TSX:NB) (OTCQX:NIOBF ) announces that it intends to offer, on a non-brokered private placement basis, up to 4,195,804 units of the Company (the
Units ) at a price of C$1.43 per Unit (the
Issue Price ) for gross proceeds to the Company of up to approximately C$6.0 million (the
Offering ). There is no minimum offering amount.
The pricing of the Units was set at a C$0.01 premium to the five-day Volume Weighted Average Price ( VWAP ) of NioCorp common shares of C$1.42 based upon the close of trading on April 16, 2021.
Each Unit will consist of one common share of NioCorp (each, a
DARZALEX® SC Becomes the First and Only Health Canada-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis, A Rare Disease newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.
O2Gold Inc. (“
O2Gold” or the “
Company”) (TSXV: OTGO) is pleased to announce that it has closed its previously announced non-brokered private placement financing (the “
Offering”). The Company issued 17,390,000 units (each, a “
Unit”) at a price of $0.20 per Unit for gross proceeds of $3,478,000. For more information on the Offering, please see the Company’s press releases dated January 14, 2021 and March 22, 2021, which are available under the Company’s profile on SEDAR at www.sedar.com.
Pursuant to the Offering, each Unit consists of one common share of the Company (each, a “
Common
Share”) and one-half of one Common Share purchase warrant (each whole warrant, a “
Janssen Showcases Phase 2 Nipocalimab (M281) Data in Adults with Generalized Myasthenia Gravis (gMG) at the 2021 American Academy of Neurology Virtual Meeting
Full results from the Vivacity-MG study to be presented for the first time during an oral presentation
News provided by
Share this article
Share this article
TITUSVILLE, N.J., April 16, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the full results from the Phase 2 Vivacity-MG study of the investigational compound, nipocalimab (M281), in generalized myasthenia gravis (gMG)–a chronic, autoimmune neuromuscular disease. The data will be featured as part of an oral presentation at the American Academy of Neurology (AAN) Virtual Meeting taking place April 17-22, 2021.
Strategic Resources Hires Vice President Finland Operations
News provided by
Share this article
Strategic Resources Inc. (TSXV: SR)
(the Company or Strategic ) announces that it has hired Jukka Pitkäjärvi as Vice President Finland Operations. Mr. Pitkäjärvi has worked for more than 30 years in the international mining and metallurgical industry. Most recently he was CEO of Ferrovan Oy, a private company developing the Mustavaara project and other vanadium projects in Finland. Mr. Pitkäjärvi holds a M.Sc in Geology and Mineralogy from University of Oulu (Finland), Business Engineering Diploma from Oulu Polytechnical University (Finland) and Business Management Diploma from POHTO - Institute for Management and Technological Training (Finland).